公开(公告)号：US20230346940A1

公开(公告)日：2023-11-02

申请号：US17756304

申请日：2020-11-20

申请人： National University of Singapore

发明人： David Michael EPSTEIN ,  Raymond LEE ,  Shu Cheng WONG

IPC分类号： A61K39/00 ,  G16B20/20 ,  G01N33/58 ,  G01N33/574 ,  C07K14/725 ,  C07K16/28 ,  C07K16/40 ,  C07K16/32

CPC分类号： A61K39/464462 ,  G16B20/20 ,  G01N33/58 ,  G01N33/574 ,  C07K14/7051 ,  C07K16/2833 ,  C07K16/40 ,  A61K39/4613 ,  A61K39/4632 ,  A61K39/464414 ,  C07K16/32 ,  C07K16/286 ,  A61K39/464401 ,  A61K2239/28

摘要： The present invention relates to a method and system for identifying and validating pairs of candidate antigens and their cognate antigen-specific T lymphocytes that are useful for validating the immunogenic activity of paired antigen and TCR sequences. The method includes, inter alia, steps of determining one or more splice variants that are more highly transcribed in a sample obtained e from cohort of patients compared to a reference sample, determining one or more amino acid sequences that occur in an amino acid translation of said one or more splice variants but not in the corresponding splice variant in the reference sample, and predicting HLA binding of the amino acid sequences in order to identify candidate shared antigen. The present invention also relates to methods of characterising and/or treating a medical condition, including cancer.

公开(公告)号：US20240277770A1

公开(公告)日：2024-08-22

申请号：US18647560

申请日：2024-04-26

申请人： GENENTECH, INC.

发明人： Hem Raj GURUNG ,  Benjamin Joseph HALEY ,  Amy Jeane HEIDERSBACH ,  Juan LI ,  Christopher Michael ROSE ,  Ann-Jay TONG ,  Craig BLANCHETTE ,  Pamela Pui Fung CHAN ,  Martine Abraham DARWISH

IPC分类号： A61K35/17 ,  A61K39/00 ,  C07K14/74 ,  C12N5/0783 ,  C12N5/09 ,  G01N33/50

CPC分类号： A61K35/17 ,  A61K39/0011 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464414 ,  C07K14/70539 ,  C12N5/0636 ,  C12N5/0694 ,  G01N33/5044 ,  C12N2510/00

摘要： The present disclosure relates to compositions and methods of uses of a monoallelic MHC-expressing cell line, as well as method of identifying a neoepitope-MHIC binding pair and methods of treating a subject having a cancer or tumor expressing a neoantigen and a MHC allele.

公开(公告)号：US20240352130A1

公开(公告)日：2024-10-24

申请号：US18685663

申请日：2022-08-23

申请人： THE CHILDREN'S HOSPITAL OF PHILADELPHIA ,  MYRIO THERAPEUTICS PTY LTD

发明人： Matthew BEASLEY ,  Ben KIEFEL ,  John MARIS ,  Mark YARMARKOVICH ,  Fiona GRACEY ,  Nickolaos SGOURAKIS ,  John WARRINGTON ,  Quinlen MARSHALL

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC分类号： C07K16/2833 ,  A61K39/4631 ,  A61K39/464414 ,  A61P35/00 ,  A61K2039/505 ,  A61K2239/47 ,  C07K2317/33 ,  C07K2317/622

摘要： The neuroblastoma immunopeptidome is enriched with peptides derived from proteins essential for tumorigenesis including the unmutated peptide QYNPIRTTF (SEQ ID NO: 1) discovered on HLA-A*24:02 which is derived from the neuroblastoma dependency gene and master transcriptional regulator PHOX2B. To target QYNPIRTTF, peptide-centric chimeric antigen receptors (PC-CARs) were developed via a counter panning strategy using predicted potentially cross-reactive peptides. Informed by computational modeling, PHOX2B peptide¬ centric CARs were demonstrated to also recognize QYNPIRTTF (SEQ ID NO: 1) presented by HLA-A*23:01 and the highly divergent HLA-B*14:02. Potent and specific killing of neuroblastoma cells expressing these HEAs in vitro was shown along with complete tumor regression in mice.

公开(公告)号：US20230293687A1

公开(公告)日：2023-09-21

申请号：US18017628

申请日：2021-07-29

申请人： Eureka Therapeutics, Inc.

发明人： Cheng Liu ,  Hongbing Zhang ,  Zhiyuan Yang ,  Pengbo Zhang ,  Yixiang Xu ,  Guangyuan Xiong ,  Ziyou Cui

IPC分类号： A61K39/00 ,  C12N15/86 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  C07K14/47 ,  C07K14/005 ,  C07K16/30 ,  C07K16/08 ,  C07K16/18 ,  C07K14/435 ,  C07K16/32 ,  C07K16/40 ,  C07K14/78 ,  C07K14/82 ,  C07K16/44 ,  C07K14/71 ,  C07K14/73 ,  C07K14/735 ,  A61P35/00

CPC分类号： A61K39/4622 ,  C12N15/86 ,  C07K14/7051 ,  C07K14/70578 ,  A61K39/4632 ,  A61K39/464417 ,  C07K14/70521 ,  C07K14/70553 ,  C07K14/70507 ,  C07K14/70503 ,  C07K14/7056 ,  C07K14/705 ,  A61K39/464411 ,  A61K39/464402 ,  A61K39/4644 ,  A61K39/4633 ,  C07K16/28 ,  C07K14/4748 ,  C07K14/005 ,  A61K39/464489 ,  A61K39/464481 ,  A61K39/464453 ,  A61K39/464414 ,  A61K39/464406 ,  C07K16/3038 ,  C07K16/303 ,  C07K16/30 ,  C07K16/2833 ,  C07K16/084 ,  A61K39/464838 ,  C07K16/18 ,  A61K39/4643 ,  C07K14/435 ,  C07K16/3069 ,  A61K39/464494 ,  C07K16/32 ,  C07K16/40 ,  C07K14/78 ,  A61K39/464454 ,  A61K39/464462 ,  C07K16/3053 ,  C07K14/70596 ,  C07K16/2896 ,  A61K39/46432 ,  A61K39/464488 ,  A61K39/464486 ,  A61K39/464449 ,  A61K39/464451 ,  C07K14/4746 ,  C07K16/3015 ,  C07K14/82 ,  C07K16/44 ,  A61K39/4645 ,  C07K14/4727 ,  C07K16/3092 ,  C07K14/71 ,  C07K16/2863 ,  A61K39/464431 ,  A61K39/464495 ,  A61K39/46441 ,  C07K14/70589 ,  A61K39/464413 ,  C07K14/70514 ,  C07K14/70535 ,  C07K14/70532 ,  A61K39/4611 ,  A61K39/4613 ,  A61P35/00 ,  C12N2740/15043 ,  C07K2319/03 ,  C07K2319/033 ,  C07K2319/035 ,  C07K2317/569 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/565

摘要： Described herein are immune cells comprising: a T-cell receptor (TCR) and a chimeric stimulating receptor (CSR) that comprises (i) a ligand-binding module that is capable of binding or interacting with a target ligand; (ii) a transmembrane domain; and (iii) a CD30 costimulatory domain, in which the CSR in the immune cells lacks a functional primary signaling domain. Also provided herein are methods of using the same or components thereof (e.g., the CSR) for therapeutic treatment of cancers (e.g., solid tumor cancers).

公开(公告)号：US20240165230A1

公开(公告)日：2024-05-23

申请号：US18282970

申请日：2022-03-18

申请人： MEDIZINISCHE HOCHSCHULE HANNOVER

发明人： Immo PRINZ ,  Malte DESEKE

IPC分类号： A61K39/00 ,  C07K14/725 ,  C12N5/0783

CPC分类号： A61K39/4632 ,  A61K39/4611 ,  A61K39/464414 ,  C07K14/7051 ,  C12N5/0636 ,  C12N2510/00

摘要： The present invention relates to the filed of immunotherapy, in particular, of lymphoproliferative disorders associated with abnormal proliferation of HLA-DR+ cells, e.g., malignancies of the hematopoietic and lymphoid tissues. The invention provides pharmaceutical compositions useful for, e.g., adoptive T cell therapy or T cell receptor (TCR) gene therapy or such disorders, as well as novel expression vectors, host cells and y8 (gamma/delta) TCR constructs. In particular, the inventors have identified γδ (gamma/delta) TCR constructs that can specifically bind to HLA-DR. In addition to host cells engineered to express such constructs that can be used for therapeutic as well as diagnostic purposes, soluble TCR constructs are provided, which can, e.g., be used in a method of detecting HLA-DR+ cells, e.g., in vitro as well as bispecific constructs that can be therapeutically used.

公开(公告)号：US20240131155A1

公开(公告)日：2024-04-25

申请号：US18273468

申请日：2022-01-21

申请人： Erasmus University Medical Center Rotterdam

发明人： Johannes Eduard Maria Antonius DEBETS ,  Dora Martha HAMMERL

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C07K16/28

CPC分类号： A61K39/4611 ,  A61K39/4632 ,  A61K39/464414 ,  A61P35/00 ,  C07K14/7051 ,  C07K16/28 ,  A61K2239/49 ,  C07K2319/02 ,  C07K2319/03

摘要： The invention provides inter alia an engineered T cell, wherein said T cell is engineered to express a T cell receptor (TCR) or an antibody-based receptor that binds to a T cell epitope of human ropporin-1A (ROPN1) or human ropporin-1B (ROPN1B); wherein said T cell epitope is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:43, SEQ ID NO:23, SEQ ID NO:56 and SEQ ID NO:24.